MetaCap

Faeth Therapeutics (FTH) vs Pyxis Oncology (PYXS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Faeth Therapeutics (FTH) has outperformed Pyxis Oncology (PYXS) over the past year, losing 9.6% versus a loss of 62.3%. Over five years, PYXS leads with a -85.9% price change compared with -95.0% for FTH. Pyxis Oncology is the larger company by market cap ($216.5 million vs $203.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FTH-9.64%PYXS-62.29%
+381%+141%-100%
Nov 21, 20251 yearNov 20, 2026
FTH-95.34%PYXS-85.99%
+5%-48%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FTH versus PYXS key metrics
MetricFTHPYXS
Share price$7.88$1.81
Market cap$203.65M$216.49M
1-day change-9.32%+7.74%
YTD return-26.15%+57.39%
1-year return-9.64%-62.29%
5-year return-94.96%-85.90%
EPS (TTM)$-22.50$-1.27
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$13.86M
Revenue growth (YoY)—-14.17%
Net income (latest FY)$-21.09M$-79.62M
Gross margin—82.77%
Operating margin—-609.18%
Net margin—-574.55%
52-week high$42.14$5.55
52-week low$7.45$1.03
Distance from 52-week high-81.30%-67.39%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+612.56%+354.14%
Average volume500.25K1.06M
Shares outstanding25.84M119.61M
Employees2956
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FTH has outperformed PYXS by 52.6 percentage points over the past year.

About Faeth Therapeutics

FTH stock →

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

About Pyxis Oncology

PYXS stock →

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees

FTH vs PYXS FAQ

Which is bigger, Faeth Therapeutics or Pyxis Oncology?

Pyxis Oncology (PYXS) is larger, with a market capitalization of $216.49M compared with $203.65M for Faeth Therapeutics (FTH).

Which stock has performed better over the past year, FTH or PYXS?

FTH returned -9.64% over the past 12 months, compared with -62.29% for PYXS (price return, excluding dividends). Past performance does not predict future results.

Are Faeth Therapeutics and Pyxis Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons